Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2025
0mins
Should l Buy INDP?
Source: Newsfilter
Clinical Trial Progress: Indaptus Therapeutics has successfully enrolled over 20 patients in the weekly dosing cohort of its Phase 1 trial for Decoy20, showing early signs of potential benefits with some patients demonstrating stable disease. The company is also preparing to initiate a combination trial with BeiGene's PD-1 inhibitor, tislelizumab.
Financial Overview: For the fiscal year ending December 31, 2024, Indaptus reported a net loss of $15 million, a slight improvement from the previous year's loss, and ended the year with $5.8 million in cash. The company plans to enhance patient enrollment and provide further clinical updates throughout 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDP
Wall Street analysts forecast INDP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.650
Low
10.00
Averages
10.00
High
10.00
Current: 1.650
Low
10.00
Averages
10.00
High
10.00
No data
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, issuing 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, which is expected to bolster the company's capital base and support future strategic developments.
- Leadership Change: David E. Lazar has been appointed Co-CEO and Chairman of the Board, while Jeffrey Meckler will continue as Co-CEO, leading the team to evaluate the company's lead product candidates and explore strategic opportunities aimed at driving shareholder value.
- Board Restructuring: Following the closing of the transaction, the Board was reconstituted with Avraham Ben-Tzvi joining, replacing the resigning Hila Kara and Dr. Robert Martell, reflecting the company's governance adjustments to align with new strategic directions.
- Shareholder Approval: The conversion of shares is contingent upon obtaining shareholder approval at the upcoming meeting expected in Q1 2026, a process that will provide crucial support for the company's future capital structure and shareholder equity.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement Reached: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, agreeing to issue 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, thereby strengthening the company's capital base to support future strategic developments.
- Management Changes: Lazar's appointment as Co-CEO and Chairman of the Board reflects the company's confidence in his leadership capabilities, which is expected to drive innovation in cancer and viral infection treatments.
- Shareholder Approval Requirement: The completion of this transaction is contingent upon shareholder approval at the upcoming meeting in Q1 2026, and if approved, Lazar will have the right to nominate up to three new directors, potentially optimizing the board structure further.
- Strategic Opportunity Exploration: Lazar indicated he will actively evaluate the company's lead product candidates while exploring strategic opportunities to enhance shareholder value, demonstrating the company's proactive stance towards transformation and growth.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
Indaptus Therapeutics Completes Board Restructuring and Raises $6 Million
- Investor Commitment: Investor David E. Lazar purchased 300,000 shares of Series AA Preferred Stock and 700,000 shares of Series AAA Preferred Stock at $6.00 per share on Monday, generating $6 million in gross proceeds, which will support the company's future initiatives.
- Board Restructuring: Lazar has been appointed as Co-CEO, enhancing leadership stability, while holding derivative securities convertible into 66 million common shares, indicating strong confidence in the company's future prospects.
- Shareholder Vote Scheduled: A special meeting is set for March 31, 2026, to approve the preferred stock conversion and elect new board members, aiming to enhance shareholder engagement and governance structure.
- Market Performance: Despite a market capitalization of $3.47 million and a 92.04% decline in stock price over the past year, Indaptus saw a 64.65% increase in after-hours trading, reflecting positive market sentiment towards the recent financing and management changes.
See More
Indaptus Therapeutics Stock Soars 64.65% to $3.26 After Securities Agreement
- Significant Stock Movement: Indaptus Therapeutics saw its stock decline 2.46% to $1.98 at close but surged 64.65% to $3.26 in after-hours trading, indicating strong investor confidence in its future potential.
- Financing Agreement: The company entered into a securities purchase agreement with investor David E. Lazar on December 22, 2025, selling 1 million shares of convertible preferred stock for $6 million, which is expected to provide financial support pending shareholder approval.
- Positive Market Reaction: Trinity Biotech's stock surged 43.50% to $1.28 after announcing a significant HIV testing order, reflecting market optimism regarding its financial stability and demand recovery.
- Pipeline Restart Approval: Sable Offshore's shares rose 36.32% to $10.36 following the U.S. Pipeline and Hazardous Materials Safety Administration's approval of the Las Flores Pipeline system restart plan, marking a critical step forward in the company's operational recovery.
See More
Indaptus Therapeutics Announces Reverse Stock Split
Reverse Stock Split Announcement: Indaptus Therapeutics has approved a one-for-twenty-eight reverse stock split of its common stock, effective after trading on June 26, 2025, to comply with Nasdaq listing requirements and attract institutional investors.
Impact on Shares: Following the split, approximately 16 million outstanding shares will be reduced to about 572 thousand, with adjustments made to options and warrants; fractional shares will be compensated in cash.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, issuing 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, which is expected to bolster the company's capital base and support future strategic developments.
- Leadership Change: David E. Lazar has been appointed Co-CEO and Chairman of the Board, while Jeffrey Meckler will continue as Co-CEO, leading the team to evaluate the company's lead product candidates and explore strategic opportunities aimed at driving shareholder value.
- Board Restructuring: Following the closing of the transaction, the Board was reconstituted with Avraham Ben-Tzvi joining, replacing the resigning Hila Kara and Dr. Robert Martell, reflecting the company's governance adjustments to align with new strategic directions.
- Shareholder Approval: The conversion of shares is contingent upon obtaining shareholder approval at the upcoming meeting expected in Q1 2026, a process that will provide crucial support for the company's future capital structure and shareholder equity.
See More
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
- Investment Agreement Reached: Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, agreeing to issue 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of Series AAA preferred stock, thereby strengthening the company's capital base to support future strategic developments.
- Management Changes: Lazar's appointment as Co-CEO and Chairman of the Board reflects the company's confidence in his leadership capabilities, which is expected to drive innovation in cancer and viral infection treatments.
- Shareholder Approval Requirement: The completion of this transaction is contingent upon shareholder approval at the upcoming meeting in Q1 2026, and if approved, Lazar will have the right to nominate up to three new directors, potentially optimizing the board structure further.
- Strategic Opportunity Exploration: Lazar indicated he will actively evaluate the company's lead product candidates while exploring strategic opportunities to enhance shareholder value, demonstrating the company's proactive stance towards transformation and growth.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
Indaptus Therapeutics Completes Board Restructuring and Raises $6 Million
- Investor Commitment: Investor David E. Lazar purchased 300,000 shares of Series AA Preferred Stock and 700,000 shares of Series AAA Preferred Stock at $6.00 per share on Monday, generating $6 million in gross proceeds, which will support the company's future initiatives.
- Board Restructuring: Lazar has been appointed as Co-CEO, enhancing leadership stability, while holding derivative securities convertible into 66 million common shares, indicating strong confidence in the company's future prospects.
- Shareholder Vote Scheduled: A special meeting is set for March 31, 2026, to approve the preferred stock conversion and elect new board members, aiming to enhance shareholder engagement and governance structure.
- Market Performance: Despite a market capitalization of $3.47 million and a 92.04% decline in stock price over the past year, Indaptus saw a 64.65% increase in after-hours trading, reflecting positive market sentiment towards the recent financing and management changes.
See More
Indaptus Therapeutics Stock Soars 64.65% to $3.26 After Securities Agreement
- Significant Stock Movement: Indaptus Therapeutics saw its stock decline 2.46% to $1.98 at close but surged 64.65% to $3.26 in after-hours trading, indicating strong investor confidence in its future potential.
- Financing Agreement: The company entered into a securities purchase agreement with investor David E. Lazar on December 22, 2025, selling 1 million shares of convertible preferred stock for $6 million, which is expected to provide financial support pending shareholder approval.
- Positive Market Reaction: Trinity Biotech's stock surged 43.50% to $1.28 after announcing a significant HIV testing order, reflecting market optimism regarding its financial stability and demand recovery.
- Pipeline Restart Approval: Sable Offshore's shares rose 36.32% to $10.36 following the U.S. Pipeline and Hazardous Materials Safety Administration's approval of the Las Flores Pipeline system restart plan, marking a critical step forward in the company's operational recovery.
See More
Indaptus Therapeutics Announces Reverse Stock Split
Reverse Stock Split Announcement: Indaptus Therapeutics has approved a one-for-twenty-eight reverse stock split of its common stock, effective after trading on June 26, 2025, to comply with Nasdaq listing requirements and attract institutional investors.
Impact on Shares: Following the split, approximately 16 million outstanding shares will be reduced to about 572 thousand, with adjustments made to options and warrants; fractional shares will be compensated in cash.
See More
